experimental medication development janssen pharmaceutica division johnson johnson treatment depressive disorders smoking acts selective positive allosteric modulator nicotinic acetylcholine receptor act nachrs serotonin receptor interact panel receptors drug found lower agonist nicotine threshold activation nachr increase maximum agonist response nachr february phase ii clinical trials depressive disorders smoking also investigation treatment schizophrenia alzheimers disease development indications drug article relating nervous system stub help wikipedia expanding